

Mometasone Cream Formulation

Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

SECTION 1. IDENTIFICATION

Product name : Mometasone Cream Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H319 Causes serious eye irritation.
H360Df May damage the unborn child. Suspected of damaging fertility.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.

Storage:
P405 Store locked up.

Mometasone Cream Formulation

Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 50 - < 70
2-Methyl-2,4-pentanediol	107-41-5	>= 10 - < 20
Titanium dioxide	13463-67-7	>= 1 - < 5
Mometasone	83919-23-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.
May damage the unborn child. Suspected of damaging fertility.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

		Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Vapors may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe vapors. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
 Date of first issue: 05/21/2017

- Keep container tightly closed.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	TWA (Mist)	5 mg/m ³	OSHA Z-1
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
		TWA (Mist)	5 mg/m ³	NIOSH REL
		ST (Mist)	10 mg/m ³	NIOSH REL
2-Methyl-2,4-pentanediol	107-41-5	C	25 ppm 125 mg/m ³	NIOSH REL
		TWA (Vapor)	25 ppm	ACGIH
		STEL (Vapor)	50 ppm	ACGIH
		STEL (Inhalable fraction, Aerosol only)	10 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.

Titanium dioxide

- Engineering measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : cream
- Color : white to off-white
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : > 199.9 °F / > 93.3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapors may form explosive mixture with air.
Can react with strong oxidizing agents.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**White mineral oil (petroleum):**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

2-Methyl-2,4-pentanediol:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Mometasone Cream Formulation

Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No skin irritation

2-Methyl-2,4-pentanediol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No eye irritation

2-Methyl-2,4-pentanediol:

Species : Rabbit

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Result : Irritation to eyes, reversing within 21 days

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Mometasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

2-Methyl-2,4-pentanediol:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Result : negative

Mometasone:

Test Type : Maximization Test
Routes of exposure : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitization.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Mometasone Cream Formulation

Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

Components:**White mineral oil (petroleum):**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Test Type: Chromosomal aberration
 Species: Rat
 Cell type: Bone marrow
 Result: negative

Test Type: unscheduled DNA synthesis assay
 Species: Rat
 Cell type: Liver cells
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rat
 Application Route : Ingestion
 Exposure time : 24 Months
 Result : negative

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Mometasone:

Species : Rat
 Application Route : Inhalation
 Exposure time : 2 Years
 Dose : 0.067 mg/kg body weight
 Result : negative

Species : Mouse
 Application Route : Inhalation
 Exposure time : 19 Months
 Dose : 0.160 mg/kg body weight
 Result : negative

IARC Group 2B: Possibly carcinogenic to humans
 Titanium dioxide

13463-67-7

OSHA No component of this product present at levels greater than or equal to 0.1% is

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**White mineral oil (petroleum):**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Skin contact
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

2-Methyl-2,4-pentanediol:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 421
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced fetal weight.
Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
Species: Rat

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
 Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Subcutaneous
 Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
 Result: Effects on newborn.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Routes of exposure : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****White mineral oil (petroleum):**

Species : Rat
 LOAEL : 160 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Mometasone Cream Formulation

Version Revision Date: SDS Number: Date of last issue: 10/10/2020
4.5 04/09/2021 1688406-00011 Date of first issue: 05/21/2017

Species : Rat
LOAEL : >= 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 4 Weeks
Method : OECD Test Guideline 412

2-Methyl-2,4-pentanediol:

Species : Rat
NOAEL : >= 450 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408

Titanium dioxide:

Species : Rat
NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 y

Mometasone:

Species : Rat
NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
NOAEL : 0.00013 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog
NOAEL : 0.0005 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Experience with human exposure**Components:****2-Methyl-2,4-pentanediol:**

Eye contact : Target Organs: Eyes
Symptoms: Irritation

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks : Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****White mineral oil (petroleum):**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l
Exposure time: 28 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 21 d

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

2-Methyl-2,4-pentanediol:

- Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to microorganisms : NOEC: 200 mg/l
Exposure time: 10 d

Titanium dioxide:

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Mometasone:

- Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
- EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.
- NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Persistence and degradability**Components:****White mineral oil (petroleum):**

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d

2-Methyl-2,4-pentanediol:

- Biodegradability : Result: Readily biodegradable.
Biodegradation: 81 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Mometasone:

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

- Stability in water : Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

Bioaccumulative potential

Components:

2-Methyl-2,4-pentanediol:

Partition coefficient: n-octanol/water : log Pow: 0
Remarks: Calculation

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil

Components:

Mometasone:

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : Miscellaneous

SAFETY DATA SHEET



Mometasone Cream Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : yes(Mometasone)
Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Serious eye damage or eye irritation

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

White mineral oil (petroleum)	8042-47-5
2-Methyl-2,4-pentanediol	107-41-5
Aluminum starch octenylsuccinate	9087-61-0
Beeswax	8006-40-4
Water	7732-18-5
Titanium dioxide	13463-67-7

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

White mineral oil (petroleum)	8042-47-5
2-Methyl-2,4-pentanediol	107-41-5

California Permissible Exposure Limits for Chemical Contaminants

White mineral oil (petroleum)	8042-47-5
2-Methyl-2,4-pentanediol	107-41-5
Titanium dioxide	13463-67-7

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET




Mometasone Cream Formulation



Version 4.5 Revision Date: 04/09/2021 SDS Number: 1688406-00011 Date of last issue: 10/10/2020
Date of first issue: 05/21/2017

NFPA 704:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
ACGIH / STEL	:	Short-term exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST	:	STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
NIOSH REL / C	:	Ceiling value not be exceeded at any time.
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable

SAFETY DATA SHEET



Mometasone Cream Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
4.5	04/09/2021	1688406-00011	Date of first issue: 05/21/2017

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8